Plasma exosomal hsa_circ_0079439 as a novel biomarker for early detection of gastric cancer
Quick Facts
- Publication title: Plasma exosomal hsa_circ_0079439 as a novel biomarker for early detection of gastric cancer
- Journal: WORLD J GASTROENTERO
- Year: 2023
- DOI: 10.3748/wjg.v29.i22.3482
- PMID/PMCID: 37389236; PMC10303519
Research overview
There were 303 participants, including 240 GC patients and 63 HDs, involved in the study. Therefore, plasma exosomal hsa_circ_0079439 might be a potential biomarker for the diagnosis of GC during both the early and late stages.
Key findings
There were 303 participants, including 240 GC patients and 63 HDs, involved in the study.
However, the levels of standard serum biomarkers were similar between the two groups.
Study design
Healthy donors (HDs) and GC patients diagnosed by pathology were recruited.
Nine GC patients and three HDs were selected for exosomal whole-transcriptome RNA sequencing.
The expression profiles of circRNAs were analyzed by bioinformatics methods and validated by droplet digital polymerase chain reaction.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, EV characterization, lncRNA/mRNA sequencing; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV lncRNA/mRNA Sequencing, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Plasma exosomal hsa_circ_0079439 as a novel biomarker for early detection of gastric cancer World journal of gastroenterology. 2023. DOI: 10.3748/wjg.v29.i22.3482. PMID/PMCID: 37389236; PMC10303519.